| Title |
Aripiprazole versus other atypical antipsychotics for schizophrenia
|
|---|---|
| Published in |
Cochrane database of systematic reviews, January 2014
|
| DOI | 10.1002/14651858.cd006569.pub5 |
| Pubmed ID | |
| Authors |
Priya Khanna, Tao Suo, Katja Komossa, Huaixing Ma, Christine Rummel-Kluge, Hany G El-Sayeh, Stefan Leucht, Jun Xia |
| Abstract |
In most western industrialised countries, second generation (atypical) antipsychotics are recommended as first-line drug treatments for people with schizophrenia. In this review, we specifically examine how the efficacy and tolerability of one such agent - aripiprazole - differs from that of other comparable second generation antipsychotics. |
Twitter Demographics
The data shown below were collected from the profiles of 22 tweeters who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 2 | 9% |
| United Kingdom | 2 | 9% |
| India | 1 | 5% |
| France | 1 | 5% |
| Canada | 1 | 5% |
| Spain | 1 | 5% |
| Unknown | 14 | 64% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 18 | 82% |
| Practitioners (doctors, other healthcare professionals) | 3 | 14% |
| Science communicators (journalists, bloggers, editors) | 1 | 5% |
Mendeley readers
The data shown below were compiled from readership statistics for 424 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Denmark | 2 | <1% |
| Spain | 2 | <1% |
| Brazil | 1 | <1% |
| South Africa | 1 | <1% |
| Uruguay | 1 | <1% |
| Guatemala | 1 | <1% |
| Chile | 1 | <1% |
| United Kingdom | 1 | <1% |
| Japan | 1 | <1% |
| Other | 0 | 0% |
| Unknown | 413 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 70 | 17% |
| Student > Bachelor | 50 | 12% |
| Researcher | 46 | 11% |
| Student > Ph. D. Student | 43 | 10% |
| Other | 26 | 6% |
| Other | 92 | 22% |
| Unknown | 97 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 140 | 33% |
| Psychology | 41 | 10% |
| Nursing and Health Professions | 31 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 26 | 6% |
| Agricultural and Biological Sciences | 15 | 4% |
| Other | 60 | 14% |
| Unknown | 111 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 28. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 September 2020.
All research outputs
#1,211,439
of 23,039,416 outputs
Outputs from Cochrane database of systematic reviews
#2,781
of 12,357 outputs
Outputs of similar age
#14,465
of 306,669 outputs
Outputs of similar age from Cochrane database of systematic reviews
#60
of 238 outputs
Altmetric has tracked 23,039,416 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,357 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 31.6. This one has done well, scoring higher than 77% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 306,669 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 238 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.